

Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer

A Virtual Workshop
January 22, 25, & 27, 2021

MONICA M. BERTAGNOLLI, MD, FACS, FASCO, PLANNING COMMITTEE CHAIR
HARPREET SINGH, MD, FOOD AND DRUG ADMINISTRATION

**WORKSHOP SPONSOR:
FOOD AND DRUG ADMINISTRATION**

WORKSHOP PLANNING COMMITTEE

Monica Bertagnolli, Brigham and Women's Hospital and Harvard Medical School (*Chair*)

Gwen Darien, National Patient Advocate Foundation

R. Donald Harvey, Emory University School of Medicine

Samir N. Khleif, Georgetown University Medical Center

Heidi Klepin, Wake Forest School of Medicine

Larissa Nekhlyudov, Harvard Medical School and Brigham and Women's Hospital

Randall A. Oyer, Penn Medicine Lancaster General Health

Rebecca D. Pentz, Emory University School of Medicine

Barbara Radziszewska, National Institute on Aging

Eric H. Rubin, Merck Research Laboratories

Ishwaria Subbiah, The University of Texas MD Anderson Cancer Center

National Academies Staff

Rachel Austin

Erin Balogh

Lori Brenig

Zaria Fyffe

Annalee Gonzales

Tracy Lustig










Sharyl Nass

Carolyn Shore

Micah Winograd

THE NATIONAL CANCER POLICY FORUM

This Forum provides a continual focus within the National Academies on **cancer**, addressing issues in **science, clinical medicine, public health, and public policy** that are relevant to the goal of reducing the cancer burden.



SPONSORS OF THE NATIONAL CANCER POLICY FORUM





Centers for Disease Control and Prevention
National Institutes of Health/National Cancer Institute
American Association for Cancer Research
American Cancer Society
American College of Radiology
American Society of Clinical Oncology
Association of American Cancer Institutes
Association of Community Cancer Centers
Bristol-Myers Squibb
Cancer Support Community
CEO Roundtable on Cancer
Flatiron Health
Merck
National Comprehensive Cancer Network
National Patient Advocate Foundation
Novartis Oncology
Oncology Nursing Society
Pfizer Inc.
Sanofi
Society for Immunotherapy of Cancer



NATIONAL
CANCER POLICY
FORUM

THE FORUM ON AGING, DISABILITY, AND INDEPENDENCE

This Forum provides a neutral venue to discuss issues that affect an **individual's ability to live independently**, focusing both on individuals who are aging with a disability and individuals who develop disabilities as they age.



SPONSORS OF THE FORUM ON AGING, DISABILITY, AND INDEPENDENCE

AARP

Administration for Community Living

American Geriatrics Society

Consumer Technology Association Foundation

LeadingAge

National Institute on Aging

National Institute on Disability, Independent Living, and Rehabilitation Research








PHI

The Gerontological Society of America

The John A. Hartford Foundation

THE FORUM ON DRUG DISCOVERY, DEVELOPMENT AND TRANSLATION

This Forum serves as a **hub** and a **catalyst** for nurturing **new ideas** and **partnerships** and offers a neutral space for stakeholders to advance critical policy discussions on **biopharmaceutical innovation** nationally and globally.



SPONSORS OF THE FORUM ON DRUG DISCOVERY, DEVELOPMENT AND TRANSLATION

Amgen Inc
Association of American Medical Colleges
AstraZeneca
Biogen
Biomedical Advanced Research and Development Authority
Burroughs Wellcome Fund
Center for Drug Evaluation and Research, U.S. FDA
Critical Path Institute
Eli Lilly and Company
FasterCures, Milken Institute
Foundation for the National Institutes of Health
Friends of Cancer Research


Johnson & Johnson
Merck & Co., Inc.
National Cancer Institute, NIH
National Center for Advancing Translational Sciences, NIH
National Institute of Allergy and Infectious Diseases, NIH
National Institute of Mental Health, NIH
National Institute of Neurological Disorders and Stroke, NIH
New England Journal of Medicine
Office of Science Policy, NIH
Sanofi
Takeda Pharmaceuticals



Forum on
**DRUG DISCOVERY, DEVELOPMENT,
and TRANSLATION**

Projected Rise in Cancer Prevalence

Estimated Cancer Prevalence by Age in the US (1975-2040)




----- Signifies the year at which the first baby boomers (those born 1946-1964) turned 65 years old

Shift in 2020:
Largest growth in
the age 75+ group

Persistent Under-representation of Older Adults

- 10-yr perspective (2005-2015)
- 105 FDA oncology trials
- 224,766 patients

Disparity is Greatest for
Patients Age ≥ 75



Singh et al, ASCO Annual Meeting, 2017

Cancer deaths

2020 projections



Volume 71, Issue 1


January/February 2021

Pages 7-33

Cancer Statistics, 2021


Rebecca L. Siegel MPH✉, Kimberly D. Miller MPH,
Hannah E. Fuchs BS, Ahmedin Jemal DVM, PhD

Prostate




■ < 60 ■ 60-79 ■ 80 and up

Breast




■ < 40 ■ 40-59 ■ 60-79 ■ 80 and up

Lung and Bronchus




■ < 40 ■ 40-59 ■ 60-79 ■ 80 and over

Colorectum



■ < 40 ■ 40-59 ■ 60-79 ■ 80 and up


Pancreas



■ < 40 ■ 40-59 ■ 60-79 ■ 80 and over


Goal of Geriatric Oncology

Improve the **evidence** base for treating older adults with cancer



Improve the **quality of care** received by older adults with cancer

Font Color



WORKSHOP GOALS

- Examine root cause that limit enrollment of older adults in cancer clinical trials
- Discuss strategies for inclusion of older adults across the drug research and development continuum
- Participant recommendations for the path forward



WORKSHOP AGENDA: FRIDAY, JANUARY 22, 2021

WELCOME AND WORKSHOP OVERVIEW

SESSION 1 Identifying Barriers and Proposing Solutions to Increasing the Evidence Base for Treating Older Adults with Cancer

SESSION 2 Study Designs to Benefit Older Adults: Approaches to Early Phase Therapeutic Development





We encourage you to ask questions of the speakers via the chatbox.

Please include your name and affiliation with your questions.

Spread the word! Tweet about the workshop using the hashtags:

#NatlCancerForum

#drugforum

#AgingDisabilityForum



(slides for Day 1 Wrap Up)

WORKSHOP AGENDA: MONDAY, JANUARY 25, 2021

SESSION 3: 1:00 pm – 4:30 pm ET

Study Designs and Policy Opportunities to Benefit Older Adults: Approaches to Clinical Trials Designed for Registrational Intent

<https://www.nationalacademies.org/event/01-25-2021/improving-the-evidence-base-for-treatment-decision-making-for-older-adults-with-cancer-a-workshop-part-2>



WORKSHOP AGENDA: WEDNESDAY, JANUARY 27, 2021

SESSION 4: 10 am – 11:35 am ET

Study Designs to Benefit Older Adults: Postmarketing Strategies and Approaches

SESSION 5: 11:50 am – 1:15 pm ET

Panel Discussion: Participant Recommendations for the Path Forward

<https://www.nationalacademies.org/event/01-27-2021/improving-the-evidence-base-for-treatment-decision-making-for-older-adults-with-cancer-a-workshop-part-3>



Cancer deaths 2020 projections




Volume 71, Issue 1

January/February 2021

Pages 7-33

Cancer Statistics, 2021

Rebecca L. Siegel MPH [✉](#), Kimberly D. Miller MPH,
Hannah E. Fuchs BS, Ahmedin Jemal DVM, PhD




FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.

	Clinical Trial Participants (2005-2015)	Cancer Incidence (2013)
<65	138077 (60%)	559949 (44%)
65-69	38664 (17%)	174886 (14%)
70-74	27578 (12%)	162483 (13%)
75-79	17544 (8%)	169510 (13%)
80+	9678 (4%)	209949 (16%)

Singh, H. et al.
Vol. 35, No. 15_suppl, May 20, 2017
2017 ASCO Annual Meeting I

Cancer deaths



Number enrolled

